BMJ Open Assessment of the quality and content of clinical practice guidelines for vitamin D and for immigrants using the **AGREE II instrument: global** systematic review

Said Yousef , 1,2 Lamia Hayawi , 3 Alomgir Hossain , 4,5 Nazmun Nahar , 5 Doug Manuel , 6 Ian Colman , 1 Emmanuel Papadimitropoulos , 7,8 MoezAllslam E Faris , 9 Leenah Abdelrazeq , 10 George A Wells , 11

To cite: Yousef S, Hayawi L, Hossain A, et al. Assessment of the quality and content of clinical practice guidelines for vitamin D and for immigrants using the AGREE II instrument: global systematic review. BMJ Open 2024;14:e080233. doi:10.1136/ bmjopen-2023-080233

Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (https://doi.org/10.1136/ bmjopen-2023-080233).

Received 28 October 2023 Accepted 08 September 2024



@ Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by

For numbered affiliations see end of article.

Correspondence to

Dr Said Yousef: sabde029@uottawa.ca

ABSTRACT

Background Worldwide, more immigrants experience vitamin D (vitD) deficiency than non-immigrants. Recommendations in current clinical practice guidelines (CPGs) concerning vitD are inadequate to address vitD deficiency among immigrants, and there are concerns regarding the quality of guidance in these CPGs.

Objectives This study aimed to identify and evaluate the quality of published CPGs addressing vitD and immigrants' health using the Appraisal of Guidelines for Research and Evaluation-II (AGREE II) tool and clarify the recommendations pertaining to vitD and immigrant populations in these CPGs.

Methods We performed a systematic search to identify the most recent CPGs across various databases (Ovid MEDLINE ALL, Embase and Turning Research Into Practice), guideline repositories and grey literature. Two reviewers independently conducted study selection and data abstraction and evaluated the quality of the included quidelines using the AGREE II tool.

Results We identified 25 relevant CPGs; 21 focused on vitD and 4 covered immigrants' health. Around one-quarter of the included CPGs were high quality (≥60% in at least four of the six domains, including 'rigour of development'). The highest mean scores among the six AGREE II domains were for 'clarity of presentation' and 'scope and purpose'. About 4.8% (1/21) of the CPGs on vitD had immigrantrelated recommendations. VitD recommendations were emphasised in one out of the four immigrant health CPGs (25%). CPGs covering immigrants' health and vitD were inadequately systematically appraised. Moreover, recommendations regarding vitD were insufficient to address the growing epidemic of vitD deficiency among immigrant populations.

Conclusion The insufficient recommendations for vitD fail to address the rising vitD deficiency among immigrants, highlighting a critical gap in healthcare provisions. Urgent national and international efforts are needed to develop comprehensive CPGs, bridging research, policy and practice disparities. Future guidelines must prioritise routine vitD screening, supplementation protocols for vulnerable immigrant groups, and culturally appropriate

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ A systematic search was conducted to identify the most recent clinical practice guidelines (CPGs) across multiple electronic databases.
- ⇒ The study employs the validated Appraisal of Guidelines for Research and Evaluation-II instrument to comprehensively assess the quality of CPGs, including whether the guideline is recommended for use, enhancing the credibility and applicability of the study findings.
- ⇒ We used the IOM definition of CPGs as statements with recommendations to optimise patient care, informed by systematic evidence review and assessment of the benefits and harms of alternative care options.
- ⇒ The study evaluates the availability of recommendations pertaining to vitamin D and immigrant populations in the related-included CPGs.
- ⇒ Only English-published CPGs were included, potentially introducing selection bias, and the intended categorisation by immigration status and region was not possible due to the limited reported data.

interventions to improve health outcomes for immigrants alobally.

PROSPERO registration number CRD42021240562.

INTRODUCTION

The rapid growth in the number of international immigrants and the global problems of vitamin D (vitD) deficiency and health deterioration among immigrants over time are expected to lead to significant burdens for the health systems of host countries. 12 Recent migrants often have better health compared with both the host country's population and earlier migrants. This 'healthy immigrant effect' is thought to arise from premigration and postmigration factors, including selective



immigration criteria favouring healthier, wealthier and better-educated individuals. Health deterioration among immigrants is a global concern their physical and mental health often declines quickly following arrival in their host countries, Mechanisms underlying this health decline in immigrants have not been explicitly identified, but previous studies suggested that it may be explained by changes in psychosocial factors and lifestyles after immigration. $^{4\,9\,10\,14\,15}$

Globally, immigrants have lower serum 25-hydroxyvitamin D (S-25(OH)D) levels compared with native-born populations. 16-18 It was recently suggested that lower levels of serum vitD may partly explain immigrants' health deterioration over time. An analysis of national Canadian data for immigrants from 153 countries and more than 13 ethnicities reported ethnicity was strongly associated with serum vitD status. 18 Non-Western immigrants were also identified by the European Calcified Tissue Society as a specific group at higher risk for vitD deficiency that should receive vitD supplementation. 19 Moreover, vitD status varies among immigrants based on skin pigmentation, clothing type, place/region of birth and resettlement changes in diet, physical activity and sun exposure. $^{16\ 20\ 21}$

Clinical practice guidelines (CPGs) are based on scientific evidence and provide up-to-date knowledge, speed the translation of research into practice, improve the effectiveness and quality of care, and decrease variations in healthcare practices. 22-24 Currently, CPGs pertaining to vitD vary among countries and organisations in terms of their scope, targeted populations and recommendations.^{25–28} The immigrant-related guidelines focused on screening, infectious diseases, mental health, chronic diseases, treatment and immunisation. 13 29 30 Notably, some of these publications lacked systematic quality appraisal,²⁹ vitD recommendations for addressing vitD deficiency in immigrant populations^{27 31} and neglecting high-risk ethnic groups. 25 27 32-34 The 2011 Canadian Immigrant and Refugee Guideline acknowledged the decline in the 'healthy immigrant effect' within the first 5 years of immigration but failed to highlight vitD deficiency as an emerging concern.¹³

Concerns have also been raised about the overall quality of available CPGs. $^{29\ 35\ 36}$ The Appraisal of Guidelines for Research and Evaluation-II (AGREE II) instrument is widely used to assess guideline quality and define information that needs to be reported and is considered a useful tool to inform guideline development. $^{37\ 38}$ AGREE II assessment covers the quality of the guideline and whether or not the guideline would be recommended for use. 38 However, previous studies that assessed the quality of CPGs using the AGREE II instrument were inconsistent in how they determined high quality. For example, with the inclusion of the 'rigour of development' domain, a high-quality score was reported as $\geq 60\%$ in at least three of the six domains, 29 four of the six domains 39 or in all six domains. 40 Therefore, to overcome gaps in knowledge

concerning vitD and immigrants' health, this systematic review aims to identify CPGs relevant to vitD and immigrants' health and systematically evaluate the quality and the content of the guidelines. In terms of content, the study sought to answer two research questions: (1) 'Do CPGs for immigrants' health include recommendations on vitD?' and (2) 'Do CPGs for vitD include recommendations for immigrants?'

METHODS

The protocol for this systematic review was registered with PROSPERO (CRD42021240562)⁴¹ and published.⁴² We followed the Cochrane methodology⁴³ to identify and select CPGs and used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) to guide the reporting.⁴⁴

Search strategy and selection of CPGs

A systematic literature search was performed to identify CPGs on vitD and immigrants/refugees worldwide. The primary search was completed in Ovid MEDLINE(R) ALL. The final search strategy was then translated to Embase Classic+Embase (Ovid), as well as the Turning Research Into Practice database. To identify relevant grey literature, we searched well-known guideline developers, such as the Guidelines International Network, Joanna Briggs Institute, WHO, Healthcare Research and Quality and the National Institute for Health and Care Excellence (NICE). Supplemental searches were performed using backward chaining (looking through the bibliographies in identified guidelines for additional relevant guidelines). The Canadian Agency for Drugs and Technologies in Health filter for searching keywords in guidelines was used. 45 46 The search was restricted to guidelines published between 2010 and 2024 and studies involving humans. The full search strategy was developed with the help of a medical librarian at Berkman Library, University of Ottawa Heart Institute. The Ovid MEDLINE search strategy is available in online supplemental file 1.

Eligibility criteria

We included guidelines that conformed to the IOM definition of CPGs 'statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options'22 and concerned immigrants' health or vitD. The fulltext guidelines included in our analysis must have been published in the English language between 2010 and 2024, with recommendations intended for healthcare professionals on screening, diagnosis, management or treatment related to immigrants' health or vitD. Any CPG concerning vitD that emphasised care for people at risk for vitD deficiency in terms of evaluation, treatment and prevention was also evaluated, without age and sex restrictions. CPGs that included immigrants as a primary population were evaluated without age and sex restrictions.




Figure 1 Literature search and inclusion flow chart (Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram). CPGs, clinical practice guidelines.

The immigrant population (including refugees and asylum seekers) was defined as those who moved cross-country or were international migrants residing in a destination country, irrespective of legal status and not limited to first-generation immigrants. 47 48

Exclusion criteria

We excluded CPGs that focused on chronic diseases, were non-English language, had incomplete text guidelines and did not consider immigrants or vitD as the primary objective. We also excluded guidelines that were not intended for healthcare practice or focused on unhealthy populations (eg, patients with osteoporosis). Evaluating evidence in nutritional guidelines is beyond the scope of this review. Furthermore, we excluded position and consensus papers as well as any other documents that were not equivalent to CPGs.

Outcomes

The primary outcome of this review was the quality score of the included CPGs based on the AGREE II tool. The secondary outcomes were recommendations relating to vitD as part of immigrant guidelines and recommendations in vitD guidelines that targeted immigrant populations.

Selection of CPGs and data extraction

We used the 'Covidence' (www.covidence.org) systematic review software to remove duplicates, screen the titles and abstracts and screen the full text of the identified CPGs. The AGREE II instrument (https://www.agreetrust.org) was used to evaluate the quality of the included guidelines. This tool comprises 23 items and evaluates six domains: 'scope and purpose', 'stakeholder involvement', 'rigour of development', 'clarity of presentation',

'applicability', and 'editorial independence'. Using an online electronic standardised form, two reviewers (SY and LH) independently evaluated and rated each CPG using a seven-point Likert scale (1=strongly disagree, 7=strongly agree). The items scoring sheet of AGREE II tool is presented in (online supplemental file 2). Furthermore, the reviewers evaluated the content of each CPG and any additional supporting documents that were cited in the published guidelines. Any disagreements regarding assessment were resolved by discussion with a third reviewer to reach consensus. Two reviewers (SY and LH) extracted the main characteristics of the included CPGs, and the extracted data were checked by a third reviewer (NN or LA).

Quality evaluation and data synthesis

The reviewers' decisions on the overall quality of recommendations contained in the guidelines were based on the context in which the AGREE II was being used. We used the mean scores for each AGREE II domain to calculate total domain scores by summing scores for individual items in a domain. The total domain score was then scaled as a percentage of the maximum possible score for that domain. The formula used to standardise the domain scores was ((actual score - minimum score)/(maximum score – minimum score)) $\times 100\%$. The range of each standardised domain score was 0%-100%. 49 The maximum possible score was obtained by multiplying the maximum score for each domain (strongly agree) by the number of items in the domain and the number of reviewers. Similarly, the minimum possible score was obtained by multiplying the minimum score for each domain (strongly disagree) by the number of items in the domain and the number of reviewers. 49 CPGs were considered high

		n=21) and immigrants-rela	,	
Author, year	Title	Organisation (country/ region)	CPG scope	Recommendation
VitD-related CPGs (n=2	1)			Recommendations for immigrants
Marcinowska- Suchowierska <i>et al</i> , 2010) ⁵⁶	Vitamin D supplementation in adults—guideline	Poland	VitD supplementation in adults	NR
Holick <i>et al</i> , 2011 ⁷⁰	Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline	Endocrine Society, US	Evaluation, treatment, and prevention of vitD deficiency	NR
WHO, 2012 ⁵⁵	Vitamin D supplementation in pregnant women	WHO, Switzerland	VitD supplementation during pregnancy	NR
Pludowski <i>et al</i> , 2013 ⁵⁷	Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe	Central Europe	VitD intake in the general population and groups at risk for vitD deficiency	NR
USPSTF, 2013 ⁵⁸	Vitamin D and calcium supplementation to prevent fractures in adults: USPSTF Recommendation Statement	USPSTF, US	VitD and calcium supplementation to prevent fractures in adults	NR
NOS, 2013 ⁵⁹	Vitamin D and bone health: A practical clinical guideline for patient management	NOS, UK	Management of vitD deficiency in adults	NR
Alberta Medical Association, 2014 ⁶⁰	Vitamin D testing and supplementation	Alberta Medical Association, Canada	VitD testing and supplementation	NR
Maeda <i>et al</i> , 2014 ⁶¹	Recommendations of the Brazilian Society of Endocrinology and Metabology for the diagnosis and treatment of hypovitaminosis D	SBEM, Brazil	Diagnosis and treatment of hypovitaminosis D	NR
NICE, 2014 ²⁶	Vitamin D: supplement use in specific population groups	NICE, UK	Prevent vitD deficiency among specific population groups	NR
SA Health Perinatal Practice, 2016 ⁶²	Vitamin D status in pregnancy	SA MNGCoP, Australia	VitD management for women and their newborns	VitD screening for "newly arrived refugees", details in online supplemental file 3
Khadilkar et al, 2017 ⁶³	Prevention and treatment of vitamin D and calcium deficiency in children and adolescents: IAP	IAP, India	Prevention and treatment of vitD and calcium deficiency in the Indian context	NR
ROS, 2018 ⁶⁴	Vitamin D and bone health: A practical clinical guideline for patient management	ROS, UK	VitD patient management	NR
Haq <i>et al</i> , 2018 ⁶⁵	Clinical practice guidelines for vitamin D in the United Arab Emirates	United Arab Emirates	Overcome the high incidence of vitD deficiency and to improve overall health	NR
	VitD-related CPGs (n=2 Marcinowska- Suchowierska et al, 2010) ⁵⁶ Holick et al, 2011 ⁷⁰ WHO, 2012 ⁵⁵ Pludowski et al, 2013 ⁵⁷ USPSTF, 2013 ⁵⁸ NOS, 2013 ⁵⁹ Alberta Medical Association, 2014 ⁶⁰ Maeda et al, 2014 ⁶¹ NICE, 2014 ²⁶ SA Health Perinatal	VitaD-related CPGs (n=21) Marcinowska-Suchowierska et al, 2010) ⁵⁶ Vitamin D supplementation in adults—guideline Holick et al, 2011 ⁷⁰ Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline WHO, 2012 ⁵⁵ Vitamin D supplementation in pregnant women Pludowski et al, 2013 ⁵⁷ Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe USPSTF, 2013 ⁵⁸ Vitamin D and calcium supplementation to prevent fractures in adults: USPSTF Recommendation Statement NOS, 2013 ⁵⁹ Vitamin D and bone health: A practical clinical guideline for patient management Alberta Medical Association, 2014 ⁶⁰ Vitamin D testing and supplementation Maeda et al, 2014 ⁶¹ Recommendations of the Brazilian Society of Endocrinology and Metabology for the diagnosis and treatment of hypovitaminosis D NICE, 2014 ²⁶ Vitamin D: supplement use in specific population groups SA Health Perinatal Practice, 2016 ⁶² Vitamin D status in pregnancy Khadilkar et al, 2017 ⁶³ Prevention and treatment of vitamin D and calcium deficiency in children and adolescents: IAP ROS, 2018 ⁶⁴ Vitamin D and bone health: A practical clinical guideline for patient management Haq et al, 2018 ⁶⁵ Vitamin D and bone health: A practice guidelines for vitamin D in the	VitD-related CPGs (n=21) Vitamin D supplementation in adults—guideline Poland Buchowierska et al., 2011 ⁷⁰ Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society, US and prevention of vitamin D deficiency: an Endocrine Society (Clinical Practice Guideline Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society (Clinical Practice Guideline WHO, Switzerland WHO, 2012 ²⁵ Vitamin D supplementation in pregnant women Central Europe Pludowski et al., 2013 ⁵⁷ Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe USPSTF, 2013 ⁵⁸ Vitamin D and calcium supplementation to prevent fractures in adults: USPSTF Recommendation Statement USPSTF, US Supplementation of the Bractures in adults: USPSTF Recommendation Statement NOS, 2013 ⁵⁸ Vitamin D and bone health: A practical clinical guideline for patient management Alberta Medical Association, 2014 ⁵⁰ Alberta Medical Association, 2014 ⁵⁰ Recommendations of the Brazilian Society of Endocrinology and Metabology for the diagnosis and treatment of hypovitaminosis D repopulation groups SBEM, Brazil NICE, 2014 ²⁶ Vitamin D: supplement use in specific population groups SA MNGCoP, Australia pregnancy Khadilkar et al, 2017 ⁶³ Prevention and treatment of vitamin D and calcium deficiency in children and adolescents: IAP IAP, India Ro	VitD-related CPGs (n=21) Marcinowska-Suchowierska et al, 2010*** Vitamin D supplementation in adults—guideline Poland Vit D supplementation in adults Holick et al, 2011*** Evaluation, treatment, and prevention of vitual in adults —guidelines or licinal Practice Guideline Evaluation, treatment, and prevention of vitid deficiency: an Endocrine Society, Clinical Practice Guideline Evaluation, treatment, and prevention of vitid deficiency WHO, 2012*** Vitamin D WHO, Switzerland Vitid supplementation during pregnancy Pludowski et al, 2013*** Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe Central Europe Vitid intake in the general population and groups at risk for vitid deficiency at risk for vitid deficiency at risk for vitid deficiency in adults. USPSTF, 2013*** Vitamin D and calcium supplementation to prevent fractures in adults: USPSTF Recommendation Statement USPSTF, US Vitid and calcium supplementation to prevent fractures in adults. NOS, 2013*** Vitamin D and bone health: A practical clinical guideline for patient management NOS, UK Management of vitid deficiency in adults Alberta Medical Association, 2014** Vitamin D testing and supplementation of the Brazilian Society of the diagnosis and treatment of the Brazilian Society of the diagnosis and treatment of the propulation groups SEM, Brazil Diagnosis and treatment of h

Continued



		ы	۹	4	-	\mathbb{C}_{0}	n	Hir	٠.	10	٦
1	ы	OI				()	ш	111	11	$I \leftarrow I$	-1

Tab	ole 1 Continued				
ID	Author, year	Title	Organisation (country/region)	CPG scope	Recommendation
14	SA Paediatric Clinical Practice Guidelines, 2018 ⁶⁶	vitamin D deficiency in children	SA Child & Adolescent Health Community of Practice, Australia	Assessment (including investigations) and management of vitD deficiency	NR
15	USPSTF, 2018 ³²	Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community- dwelling adults	USPSTF, US	VitD supplementation, with or without calcium to prevent fractures	NR ,
16	BC Guidelines, 2019 ³³	Vitamin D testing	Medical Services Commission, BC, Canada	VitD testing in the general population in B	NR C
17	WHO, 2020 ³⁴	WHO antenatal care recommendations for a positive pregnancy experience Nutritional interventions update: Vitamin D supplements during pregnancy	WHO, Geneva, Switzerland	VitD supplements durir pregnancy	g NR
18	USPSTF, 2021 ⁶⁷	Screening for Vitamin D Deficiency in Adults: USPSTF Recommendation Statement	USPSTF, US	Screening and early treatment including the benefits and harms	NR
19	Casado 2021 ⁶⁸	SEIOMM recommendations on the prevention and treatment of vitamin D deficiency	SEIOMM, Spain	Preventing and treating vitamin D deficiency	NR
20	Gupta <i>et al</i> , 2021 ⁶⁹	Indian Academy of Pediatrics Revised (2021) Guidelines on Prevention and Treatment of Vitamin D Deficiency and Rickets	IAP, India	The role of vitD supplementation during infancy and childhood	NR 9
21	Pludowski et al, 2023 ⁵⁴	Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland	PSPED, Poland	Prevention, diagnosis, and treatment of vitD deficiency	NR
	Immigrant-related CP	Gs (n=4)			Recommendations for VitD
1	Pottie <i>et al</i> , 2011 ¹³	Evidence-based clinical guidelines for immigrants and refugees	CCIRH, Canada	recommendations for immigrants and	NR, (the topic of vitD deficiency was unrecognised and reported by the panel as a limitation of this CPG)
2	Chaves <i>et al</i> , 2016 ⁷¹	Recommendations for comprehensive post-arrival health assessment for people from refugee-like backgrounds	ASID and RHeaNA, Australia	newly arrived people (refugees)	Check vitD, risk factor for low vitD, treat low vitD and ensure adequate calcium intake, sun exposure and self-management, details in online supplemental file 3
3	Tosti <i>et al</i> , 2021 ⁷²	Health assessment for migrants and asylum seekers on arrival and while hosted in reception centres		Health assessments for migrants and asylum seekers on their arrival	NR

Continued

Table	1 Continue
	OULTITUE

Immigrant-r	elated Cl	PGs (n=4)			Recommendations for VitD
4 Vignier et al,	2022 ⁷³	Public health issues and health rendezvous for migrants from conflict zones in Ukraine: A French practice guideline	HCSP, France	Medical examination of migrants and health situation of people leaving conflict zones in Ukraine	NR

ASID and RheaNA, Australasian Society for Infectious Diseases and Refugee Health Network; BC, British Columbia; CCIRH, Canadian Collaboration for Immigrant and Refugee Health; CPG, clinical practice guideline; HCSP, High Council for Public Health; IAP, Indian Academy of Pediatrics; MNGCoP, Maternal, Neonatal & Gynaecology Community of Practice; NA, not applicable; NICE, National Institute of Health and Care Excellence; NOS, National Osteoporosis Society; NR, no recommendations; PSPED, Polish Society of Pediatric Endocrinology and Diabetes; ROS, Royal Osteoporosis Society; SA, South Australian; SBEM, Brazilian Society of Endocrinology and Metabology; SEIOMM, Spanish Society for Bone Research and Mineral Metabolism; USPSTF, U.S. Preventive Services Task Force; VitD, vitamin D.

quality when the score was \geq 60% in at least four of the six domains, including the 'rigour of development' domain. Agreement between the two reviewers was assessed for the 23 items using two-way, random, single unit, absolute agreement intraclass correlation coefficients (ICC). Based on previous research, we classified an ICC of <0.40 as poor or fair, 0.40–0.60 as moderate, 0.61–0.80 as good and 0.81–1.00 as excellent. The availability of recommendations for vitD in immigrant guidelines and the inclusion of 'immigrant populations' in vitD guidelines were reported descriptively.

Patient and public involvement

Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

RESULTS

The PRISMA flow diagram (figure 1) shows the systematic process we followed to include studies captured by the electronic search. In total, 5016 citations were returned by our search. After removing duplicates and screening titles and abstracts, 231 articles were identified for full-text review. We excluded 206 articles after the full-text review because they were not a guideline or a CPG (ie, position statement, consensus or recommendation only), not in English, duplicate records, summary of a CPG, or other reasons (eg, unhealthy population or wrong intervention).

We identified 25 records as CPGs; 21 addressed vitD²⁶ ^{32–34} ^{54–70} and 4 focused on immigrants' health. ¹³ ^{71–73} Eleven CPGs were from Europe, ²⁶ ³⁴ ^{54–57} ⁵⁹ ⁶⁴ ⁶⁸ ⁷² ⁷³ seven were from North America, ¹³ ³² ³³ ⁵⁸ ⁶⁰ ⁶⁷ ⁷⁰ three were from Australia, ⁶² ⁶⁶ ⁷¹ three were from Asia ⁶³ ⁶⁵ ⁶⁹ and one was from South America. ⁶¹ The majority of CPGs (22/25; 92%) were developed by official organisations such as academic institutions, governments, health associations or guideline development organisations. The remaining three guidelines were developed by non-official organisations such as researchers, university faculty members and a conference scientific committee. ⁵⁶ ⁵⁷ ⁶⁵ Five of the

included CPGs were described as updates of previously published guidelines. ^{54 60 64 66 67} To ensure comprehensive coverage and accuracy, both the updated guidelines and their original versions were reviewed in terms of content to confirm that all recommendations were systematically assessed.

Risk factors for vitD deficiency were identified in most of the 21 CPGs focused on vitD. The most commonly reported risk factors were darker skin (especially Africans); non-Caucasian race; obesity; limited sunlight exposure (including concealing clothing); people with kidney, liver, and inflammatory bowel diseases; pregnant and lactating women; older people; and vegetarians (especially vegans). Recommendations on vitD for newly arrived refugees were only considered in one guideline. This guideline emphasised the importance of vitD screening at the first appointment for darkerskinned women (eg, Aboriginal, North African, Indian and Sri Lankan women) and newly arrived refugees. The guideline-related recommendations are presented in online supplemental file 3.

One of the four immigrants' health CPGs⁷¹ recommended checking 'vitamin D status as part of the initial health assessment if there are one or more risk factors for low vitamin D'. Moreover, that guideline recommended 'treating people with low vitamin D to restore their levels to the normal range with either daily dosing or high dose therapy, ensuring adequate calcium intake, paired with advice about sun exposure and self-management'. Screening and treating people with ongoing risk factors may require ongoing monitoring and management throughout the person's lifespan. That guideline also recommended testing S-25(OH)D levels among recent arrivals and repeating this testing at the end of the first winter in the host country (Australia) to help in making clinical judgments on the frequency of dosing.⁷¹ Moreover, the guideline outlines specific dosage recommendations based on the severity of vitD deficiency and age groups, ensuring appropriate supplementation. The detailed guideline-related recommendations are presented in table 1 and online supplemental file 3. In

ID Author, year Scope and Numbers Stakeholder purpose Rigour of development Applicability presentation Editorial independence VILL - nelated CPCs (n-27) 0 3 0 28 0 0 0 1 Mexicliowaskie Suchrowierska et al., 2011*** 56 58 100 75 0 0 0 4 Pinclowski et al., 2011*** 100 89 100 75 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100	Table 2	AGREE II total score (%) for each domain of the included CPGs	the included C	PGs				
None in a control of	<u></u>	Author, year		Stakeholder involvement	Rigour of development	Clarity of presentation	Applicability	Editorial independence
Marcinowska-Suchowierska et al, 2010** 0 3 0 28 0 Hollick et al, 2011** 56 58 73 63 52 Hollick et al, 2011** 100 66 75 52 Pludovski et al, 2013** 81 56 8 53 4 Pludovski et al, 2013** 81 56 42 44 67 35 NOS, 2013** 56 42 40 67 55 33 Alberta Medical Association, 2014** 67 64 94 64 25 NOS, 2013** 64 39 40 83 31 Alberta Medical Association, 2014** 67 64 56 83 31 NOS, 2013** 64 39 10 66 15 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67	VitD-re	lated CPGs (n=21)						
Holick et al., 2011 ⁷⁰ WHO, 2012 ⁵⁵ WHO, 2012 ⁵⁵ WHO, 2012 ⁵⁵ Hollowski et al., 2013 ⁵⁷ Alberta Medical Association, 2014 ⁶⁷ BC Guidelines, 2019 ⁶⁸ Alberta Alberta Medical Association and a series of a ser	-	Marcinowska-Suchowierska et al, 2010 ⁵⁶	0	က	0	28	0	0
WHO, 2012*** 100 88 100 75 Pludovski et al, 2013*** 42 56 8 53 4 Pludovski et al, 2013*** 81 56 8 53 4 NOS, 2013*** 56 44 64 64 55 35 Alberta Medical Association, 2014** 58 44 67 67 83 31 NOCS, 2014*** 58 44 62 83 31 83 31 NICE, 2014*** 58 44 52 83 31 83 31 NICE, 2014*** 58 44 52 83 31 15 90 Khadilkar et al, 2014*** 56 25 31 75 91 90 15 ROS, 2018*** 64 39 17 61 40 90 16 40 Sol Series 87 67 67 67 67 64 80 90 90 90 90 <td>2</td> <td>Holick <i>et al</i>, 2011⁷⁰</td> <td>56</td> <td>58</td> <td>73</td> <td>83</td> <td>52</td> <td>62</td>	2	Holick <i>et al</i> , 2011 ⁷⁰	56	58	73	83	52	62
Pludowski et al, 2013 ³⁷ 42 56 8 53 4 USPSTF, 2013 ³⁸ 81 56 50 67 35 NOS, 2013 ³⁸ 56 42 44 56 33 Aberta Medical Association, 2014 ³⁸ 67 44 52 83 31 Abrack at al, 2014 ³⁸ 64 39 10 56 15 NICE, 2014 ³⁸ 64 39 10 56 15 NICE, 2014 ³⁸ 64 39 10 56 15 NICE, 2014 ³⁸ 64 39 10 56 15 Rodikilkar et al, 2013 ³⁸ 17 61 40 56 15 Rodikilkar et al, 2013 ³⁸ 67 67 67 67 67 67 67 SA Pacidatric Clinical Practice Guidelines, 2013 ³⁸ 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 67 <td< td=""><td>ო</td><td>WHO, 2012⁵⁵</td><td>100</td><td>88</td><td>100</td><td>100</td><td>75</td><td>100</td></td<>	ო	WHO, 2012 ⁵⁵	100	88	100	100	75	100
USPSTF, 2013** 81 58 60 67 35 NOS, 2013** 56 42 44 64 25 Alberta Macical Association, 2014** 67 40 64 25 Alberta Macical Association, 2014** 67 40 83 31 NICE, 2014** 64 39 10 56 15 NINCE, 2014** 64 39 10 56 15 Khadilkar et al, 2017** 64 39 17 61 40 ROS, 2018** 47 33 17 61 40 ROS, 2018** 47 33 17 61 40 SA Pacidiatric Clinical Practice Guidelines, 2019** 27 67 67 64 50 USPSTF, 2018** 67 67 67 64 97 64 50 USPSTF, 2018** 67 67 67 67 64 50 40 USPSTF, 2021** 69 73 67 75<	4	Pludowski <i>et al</i> , 2013 ⁵⁷	42	56	80	53	4	0
NOS, 2013*** 56 42 44 64 25 Alberta Medical Association, 2014*** 67 40 83 33 Maeda et al, 2014*** 58 44 52 83 31 NICE, 2014*** 64 39 10 56 15 Khadilkar et al, 2017*** 58 53 19 56 15 Khadilkar et al, 2017*** 36 25 31 75 19 Haq et al, 2018*** 47 33 17 61 40 SA Paediatric Clinical Practice Guidelines, 2018** 2 39 10 10 SA Paediatric Clinical Practice Guidelines, 2018** 67 67 64 50 10 USPSTF, 2018*** 67 67 67 64 50 10 USPSTF, 2018*** 67 67 67 64 56 40 USPSTF, 2021*** 67 67 67 67 67 67 67 Casado 2021*** 61	2	USPSTF, 2013 ⁵⁸	81	58	50	29	35	71
Alberta Medical Association, 2014 ⁸⁰ 67 67 40 83 33 Maeda et al, 2014 ⁸¹ 58 44 52 83 31 NICE, 2014 ⁸² 64 39 75 94 90 SA Health Perinatal Practice, 2016 ⁸² 64 39 10 56 15 Knadilkar et al, 2017 ⁸³ 36 25 31 75 19 Haq et al, 2018 ⁸² 47 33 17 61 40 SA Paediatric Clinical Practice Guidelines, 2019 ⁸³ 25 36 6 39 10 USPSTF, 2018 ⁸² 67 67 67 62 64 50 USPSTF, 2018 ⁸³ 67 67 67 62 64 50 USPSTF, 2018 ⁸³ 67 67 67 67 67 62 64 50 USPSTF, 2018 ⁸³ 67 67 67 67 64 56 USPSTF, 2021 ⁸³ 67 67 67 67 67	9	NOS, 2013 ⁵⁹	56	42	44	64	25	50
Maeda et al, 2014 ⁸¹ 58 44 52 83 31 NICE, 2014 ⁸³ 92 75 94 90 SA Health Perinatal Practice, 2016 ⁸² 64 39 10 56 15 Khadilkar et al, 2017 ⁸³ 58 53 19 50 12 Hog et al, 2018 ⁶⁴ 47 33 17 61 40 Haq et al, 2018 ⁶⁵ 47 53 17 61 40 Lyp STF, 2018 ⁶⁵ 67 67 62 64 50 Los PSTF, 2018 ⁶⁵ 67 67 64 50 90 WHO, 2020 ⁶⁴ 94 86 94 97 81 WHO, 2020 ⁶⁴ 97 69 73 92 40 Casado 2021 ⁶⁸ 64 39 67 75 71 Gulda et al, 2021 ⁶⁸ 64 39 78 81 81 Gulda et al, 2016 ⁷⁷ 72 48 78 88 81 Chaves e	7	Alberta Medical Association, 2014 ⁶⁰	29	29	40	83	33	62
NICE, 2014 ²⁶ SA Health Perinatal Practice, 2016 ²⁶ SA Health Perinatal Practice, 2016 ²⁶ Khadilkar et al, 2017 ²⁶³ FKobadilkar et al, 2018 ²⁶⁴ BCS, 2018 ²⁶⁴ Haq et al, 2018 ²⁶⁵ APPROS, 2018 ²⁶⁴ BC Gasado 2021 ²⁶⁸ BC Gasado 2021 ²⁶⁸ Gupta et al, 2021 ²⁶⁸ Bulcowski et al, 2023 ²⁴⁸ BC Chaves et al, 2011 ³³ Chaves et al, 2011 ³³ BC Chaves et al, 2021 ³²⁸ BC Chave et al,	œ	Maeda <i>et al</i> , 2014 ⁶¹	58	44	52	83	31	50
SA Health Perinatal Practice, 2016 ⁸² 64 39 10 56 15 Khadilkar et al, 2017 ⁸³ 58 53 19 50 12 ROS, 2018 ⁸⁴ 36 25 31 75 19 Haq et al, 2018 ⁸⁴ 47 33 17 61 40 SA Pacdiatric Clinical Practice Guidelines, 2018 ⁸⁴ 22 36 6 40 40 USPSTF, 2018 ⁸⁴ 67 67 62 64 50 10 USPSTF, 2018 ⁸⁴ 67 67 44 64 58 WHO, 2020 ⁸⁴ 67 67 44 64 58 USPSTF, 2021 ⁸⁶ 67 67 44 64 58 USPSTF, 2021 ⁸⁶ 67 69 73 87 40 Guipta et al, 2021 ⁸⁶ 61 58 48 69 38 Poutlowski et al, 2016 ⁷¹ 72 44 86 73 78 17 Pottie et al, 2011 ⁷² 72 94	0	NICE, 2014 ²⁶	92	92	75	94	06	71
Khadilkar et al, 2017 ⁸³ 58 53 19 50 12 ROS, 2018 ⁶⁴ 36 25 31 75 19 Haq et al, 2018 ⁶⁵ 47 33 17 61 40 SA Paediatric Clinical Practice Guidelines, 2018 ⁶⁵ 67 67 67 67 67 67 67 67 67 67 67 69 70 81 USPSTF, 2018 ⁶⁵ 67 67 67 64 97 81 40 82 40 81 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82 40 82	10	SA Health Perinatal Practice, 2016 ⁶²	64	39	10	56	15	0
HOGs, 2018 ⁶⁴ 36 25 31 75 19 Haq et al, 2018 ⁶⁵ 47 33 17 61 40 SA Paediatric Clinical Practice Guidelines, 2019 ⁸³ 67 67 67 67 64 50 USPSTF, 2018 ⁸² 67 67 67 64 56 40 50 WHO, 2020 ³⁴ 94 86 94 97 81 40 58 40 58 40 58 40 58 40 58 40 58 40 58 40 58 40 58 40 58 40 58 40 58 40 59 40 59 40 59 40 59 40 50 51 40 58 40 51 40 51 40 58 51 40 51 40 51 40 51 51 51 51 51 52 51 52 51 51 51<	1	Khadilkar e <i>t al</i> , 2017 ⁶³	58	53	19	50	12	71
Haq et al, 2018 ⁶⁶ 47 33 17 61 40 SA Paediatric Clinical Practice Guidelines, 2018 ⁶⁶ 29 6 39 10 USPSTF, 2018 ³² 67 67 67 64 50 BC Guidelines, 2019 ³³ 67 67 64 58 WHO, 2020 ³⁴ 94 86 94 97 81 WHO, 2020 ³⁴ 97 69 73 92 40 Casado 2021 ⁶⁶ 64 39 67 75 21 Gupta et al, 2021 ⁶⁹ 61 58 48 69 38 Pludowski et al, 2021 ⁶⁹ 53 44 23 78 21 Migrant-related CPGs (n=4) 72 86 79 88 88 62 Pottie et al, 2011 ⁷¹ 72 86 79 88 77 77 Tosti et al, 2021 ⁷² 94 97 86 97 77 77 Viginier et al, 2022 ⁷³ 39 31 12 38 21 71	12	ROS, 2018 ⁶⁴	36	25	31	75	19	58
SA Paediatric Clinical Practice Guidelines, 2018 ⁸⁶ 22 36 6 10 USPSTF, 2018 ⁸² 67 67 67 67 67 50 BC Guidelines, 2019 ⁸³ 67 67 64 58 78 81 WHO, 2020 ⁸⁴ 94 86 94 97 81 USPSTF, 2021 ⁶³ 64 39 67 75 40 Casado 2021 ⁶³ 61 58 48 69 38 Gupta et al, 2021 ⁶³ 53 44 23 78 21 migrant-related CPGs (n-4) 72 86 78 88 Pottie et al, 2011 ¹³ 72 86 79 88 Chaves et al, 2016 ⁷¹ 72 86 77 77 Vignier et al, 2021 ⁷² 94 97 86 77 Vignier et al, 2022 ⁷³ 39 31 12 77	13	Haq e <i>t al</i> , 2018 ⁶⁵	47	33	17	61	40	0
USPSTF, 2018 ²² 67 67 67 67 67 67 64 50 BC Guidelines, 2019 ³³ 67 67 44 64 58 WHO, 2020 ³⁴ 94 94 97 81 USPSTF, 2021 ⁶³ 64 39 67 75 40 Casado 2021 ⁶³ 61 58 48 69 38 Gupta et al, 2021 ⁶³ 61 58 44 23 78 21 migrant-related CPGs (n=4) Pottie et al, 2011 ¹³ 72 86 79 88 Chaves et al, 2011 ¹³ 72 86 79 88 Tosti et al, 2021 ⁷² 94 97 85 97 77 Viginier et al, 2022 ⁷³ 39 31 12 36 21	4	SA Paediatric Clinical Practice Guidelines, 2018 ⁶⁶	22	36	9	39	10	0
BC Guidelines, 2019 ³³ 67 67 44 64 58 WHO, 2020 ³⁴ 94 86 94 97 81 USPSTF, 2021 ⁶³ 64 39 67 75 21 Casado 2021 ⁶⁸ 64 39 67 75 21 Gupta et al, 2021 ⁶³ 61 58 48 69 38 Pludowski et al, 2023 ⁵⁴ 53 44 23 78 21 migrant-related CPGs (n=4) Pottie et al, 2011 ¹³ 72 86 79 92 88 Chaves et al, 2016 ⁷¹ 72 94 48 86 62 88 Tosti et al, 2021 ⁷² 94 97 85 97 77 77 Viginier et al, 2022 ⁷³ 39 31 12 36 21 71	15	USPSTF, 2018 ³²	29	29	62	64	50	83
WHO, 2020³4 94 86 94 97 81 USPSTF, 2021⁵8 64 39 73 92 40 Casado 2021⁶8 64 39 67 75 21 Gupta et al, 2021⁶8 61 58 48 69 38 Pludowski et al, 2021⁶8 53 44 23 78 21 migrant-related CPGs (n=4) 72 86 79 92 88 Pottie et al, 2011³ 72 94 48 86 62 Chaves et al, 2016³¹ 97 77 77 Vignier et al, 2021³³ 39 31 12 36 21	16	BC Guidelines, 2019 ³³	29	29	44	64	58	50
USPSTF, 2021 ⁶⁷ 97 69 73 92 40 Casado 2021 ⁶⁸ 64 39 67 75 21 Gupta et al, 2021 ⁶⁹ 61 58 48 69 38 Pludowski et al, 2023 ⁵⁴ 53 44 23 78 21 migrant-related CPGs (n=4) 72 86 79 92 88 Pottie et al, 2011 ³ 72 94 48 86 62 Chaves et al, 2016 ⁷¹ 72 94 48 86 62 Tosti et al, 2021 ⁷² 94 97 85 97 77 Vignier et al, 2022 ⁷³ 39 31 12 36 21	17	WHO, 2020 ³⁴	94	86	94	26	81	96
Casado 2021 ⁶⁸ 64 39 67 75 21 Gupta et al, 2021 ⁶⁹ 61 58 48 69 38 Pludowski et al, 2023 ⁵⁴ 53 44 23 78 21 migrant-related CPGs (n=4) 72 86 79 92 88 Pottie et al, 2011 ⁷¹ 72 94 48 86 62 Tosti et al, 2021 ⁷² 94 97 85 97 77 Vignier et al, 2022 ⁷³ 39 31 12 36 21	18	USPSTF, 2021 ⁶⁷	97	69	73	92	40	100
Gupta et al, 2021696158486938Pludowski et al, 2023545344237821migrant-related CPGs (n=4)7286799288Pottie et al, 201137294488662Tosti et al, 2021729497859777Vignier et al, 2022733931123621	19	Casado 2021 ⁶⁸	64	39	29	75	21	12
Pludowski et al, 2023 ⁵⁴ 53 44 23 78 21 migrant-related CPGs (n=4) 72 86 79 92 88 Pottie et al, 2016 ⁷¹ 72 94 48 86 62 Chaves et al, 2021 ⁷² 94 97 85 97 77 Vignier et al, 2022 ⁷³ 39 31 12 36 21	20	Gupta e <i>t al</i> , 2021 ⁶⁹	61	58	48	69	38	71
72 86 79 92 88 72 94 48 86 62 94 97 85 97 77 39 31 12 36 21	21	Pludowski <i>et al</i> , 2023 ⁵⁴	53	44	23	78	21	92
Pottie et al, 2011 13 7286799288Chaves et al, 2016 71 7294488662Tosti et al, 2021 72 9497859777Vignier et al, 2022 73 3931123621	Immigr	ant-related CPGs (n=4)						
Chaves <i>et al</i> , 2016^{71}	-	Pottie <i>et al</i> , 2011 ¹³	72	86	79	92	88	100
Tosti <i>et al</i> , 2021 ⁷² 94 97 85 97 77 77 Vignier <i>et al</i> , 2022 ⁷³ 39 31 12 36 21	2	Chaves <i>et al</i> , 2016 ⁷¹	72	94	48	98	62	79
Vignier <i>et al</i> , 2022 ⁷³ 39 31 12 36 21	ဗ	Tosti <i>et al</i> , 2021 ⁷²	94	26	85	26	77	96
	4	Vignier <i>et al</i> , 2022 ⁷³	39	31	12	36	21	29

BC, British Columbia; CPGs, clinical practice guidelines; NICE, National Institute of Health and Care Excellence; NOS, National Osteoporosis Society; ROS, Royal Osteoporosis Society; SA, South Australian; USPSTF, U.S. Preventive Services Task Force; vitD, vitamin D.

BMJ Open: first published as 10.1136/bmjopen-2023-080233 on 10 October 2024. Downloaded from http://bmjopen.bmj.com/ on October 12, 2024 by guest. Protected by copyright.




Figure 2 Overall Appraisal of Guidelines for Research and Evaluation-II scores for each domain.

another guideline, the expert panel responsible for developing the guideline initially failed to acknowledge vitD deficiency among immigrants. Subsequently, the panel identified this issue as an emerging health concern and reported it as a limitation of their CPG. ¹³

In terms of quality, we found that nearly one-quarter of the included CPGs (7/25, 28%) were scored as high quality (\geq 60% in at least four of the six domains, including 'rigour of development'). ¹³ ²⁶ ³² ³⁴ ⁵⁵ ⁶⁷ ⁷² The three highest total AGREE II domain scores were for the two CPGs developed by the national institute for health, migration and poverty, Italy⁷² and an international organisation (WHO) ³⁴ ⁵⁵ (table 2).

The overall ICC consistency between the AGREE II appraisers was good, with a mean (range) of 62% (47%–90%). Table 1 and online supplemental file 4 presents the ICC results. The mean (SD) scores for the six AGREE II domains were 62.4% (23.9%) for scope and purpose, 57.3% (24.3%) for stakeholder involvement, 46.4% (28.8%) for rigour of development, 71.4% (20.1%) for clarity of presentation, 39.9% (26.8%) for applicability and 59.0% (36.0%) for editorial independence (figure 2).

DISCUSSION

Although vitD deficiency among immigrants is a global issue that was detected more than five decades ago, ¹³ ¹⁶ ¹⁷ ²⁹ ⁷⁴ ⁷⁵ available vitD CPGs were country specific and varied in their recommendations. Moreover, few of these publications met the criteria for guideline development, as not all were defined as CPGs, and only one considered the immigrant population in the recommendations. ⁶² The scope of most of the vitD's CPGs focused on management and supplementation,

none of them explicitly mentioned treatment or supplementation recommendations tailored to immigrant populations. One of the four immigrants' health CPGs focused on immigrants' health covered vitD testing and treatment.⁷¹ The included CPG outlines specific dosage recommendations based on the severity of vitD deficiency and age groups, ensuring appropriate supplementation as shown in online supplemental file 3. The topic of vitD deficiency was highlighted as a limitation in another immigrant's CPG.¹³

Our analysis showed that CPGs for vitD and those for immigrants' health tended to be relatively poor in terms of acknowledging the growing vitD deficiency among vulnerable immigrant populations, both in general and in specific groups (eg, refugees and certain ethnicities/origins). A recent publication focused on Canadian immigrants found that ethnicity was strongly associated with S-25(OH)D levels, with the highest deficiency levels among immigrants who were born in Morocco (55.9%), India (34.4%) and Lebanon (about 30%) compared with native-born Canadians (7.45%). Moreover, compared with the white ethnic grouping, the Japanese had the highest level of vitD deficiency, followed by Arabs and Southeast Asians. 18

Based on AGREE II scores, nearly one-quarter of the included CPGs were evaluated as high quality. The quality of CPGs was associated with the developer (eg, well-known international organisations), with the three highest quality CPGs being those from the WHO (2012), ⁵⁵ WHO (2020)³⁴ and the national institute for health, migration, and poverty, Italy (2021). ⁷⁴ The quality of the included CPGs was not associated with the publication year (result not shown), which was consistent with some



of the previous systematic reviews, ^{39 76} but contrasted with others. ^{29 40 50} Consistent with previous studies, ^{29 39 77} the mean scores for the 'clarity of presentation' and 'scope and purpose' domains in our study were better than those for the other domains. We believe that including 'rigour of development' as an important domain for quality assessment offered a more meaningful quality evaluation method. The mean quality score for the rigour of development domain in this study was low (46.4%), although there were large variations in this domain among the included CPGs (eg, SD 29.5%). This domain was highest in the two WHO CPGs (2012 and 2020). ^{34 55}

In addition to the incorrect identification of some guidelines as CPGs and the low-quality of available CPGs that were not fully being used in practice, our study highlighted an urgent need for both national and international CPGs that address the growing problem of vitD deficiency among immigrants. Only one of the 21 CPGs focused on vitD⁶² considered immigrants (newly arrived refugees) as being at risk for low vitD and recommended vitD screening at the first appointment, although most CPGs identified and highlighted darker skin as a risk factor.

A recent national cross-sectional population-based analysis in Canada evaluated the relationship between melanin levels (skin pigmentation) and S-25(OH)D among immigrants based on their ethnicity and region/country of birth compared with non-immigrants. That study revealed that melanin had a weak positive correlation with S-25(OH)D levels that may be attributable to different confounding and inherited factors related to certain ethnicities, despite the level of skin pigmentation.

In addition, a previous study highlighted the need for a global guideline that specifies subimmigrant populations for which the evidence and recommendations may differ from the overall immigrant population.⁷⁹ Therefore, it is necessary to develop CPGs based on the latest available evidence. CPGs bridge the gaps between research, policy and practice and support vitD screening and supplementation for vulnerable immigrant populations, including those from certain ethnicities/origins or groups at particular risk. It is also important that such guidelines also reflect culturally appropriate interventions that consider people of different religious faiths.

Strengths and limitations of this study

The present systematic review focused on guidelines that were defined as CPGs and intended to improve the effectiveness and quality of care and decrease variations in healthcare practices among the targeted populations based on scientific evidence. This study reduced the knowledge gap by exploring an area that has not been investigated in previous systematic reviews pertaining to this topic. As translating CPGs from other languages was a concern in this study, we only included CPGs that were published in English and excluded those for which the full text was found in other languages, which might have introduced selection bias.

In our protocol for this systematic review, ⁴² we planned to categorise available information based on immigration status (general immigrants, refugees and asylum seekers), ethnicity, region/country of birth, host country and other factors (eg, type of interventions) depending on their availability in the included guidelines. However, we were unable to specify or categorise information by immigrant subgroups, country or intervention type because of the limited information regarding vitD; that is, relevant recommendations in only one immigrant's health CPG⁷¹ and one vitD CPG. ⁶²

Conclusion

We found the identified CPGs for immigrants' health and vitD were inadequately systematically appraised in terms of quality. Moreover, the current available recommendations for vitD were insufficient to address the growing epidemic of vitD deficiency among immigrant populations. Therefore, we support previous recommendations regarding the need for national and international CPGs that respond to the growing problem of vitD deficiency among immigrants. Gathering evidence regarding vitD screening and supplementation for specific vulnerable immigrant population groups (eg, those from different ethnicities or origins) will support the development of CPGs that can bridge the gaps between research, policy and practice. It is also important that such guidelines recommend interventions that are appropriate for different faiths and cultures.

Author affiliations

¹School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada

²University of Ottawa Heart Institute Cardiovascular Devices Research Laboratory, Ottawa, Ontario, Canada

³Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

⁴The Hospital for Sick Children, Toronto, Ontario, Canada

⁵University of Ottawa Heart Institute, Ottawa, Ontario, Canada

⁶Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario. Canada

⁷Eli Lilly Canada, Toronto, Ontario, Canada

⁸University of Toronto Leslie Dan Faculty of Pharmacy, Toronto, Ontario, Canada

⁹Department of Clinical Nutrition and Dietetics, Faculty of Allied Medical Science

⁹Department of Clinical Nutrition and Dietetics, Faculty of Allied Medical Sciences, Applied Sciences Private University, Amman, Jordan

¹⁰Health Sciences, Carleton University, Ottawa, Ontario, Canada

¹¹Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada

X Said Yousef @NA

Acknowledgements We thank Sarah Visintini, MLIS (Berkman Library, University of Ottawa Heart Institute), and Becky Skidmore, MLIS, Ottawa, ON, for peer review the MEDLINE search strategy.

Contributors SY, LH, AH, DM, IC, EP and GAW conceived the study. SY designed and executed the search strategy. SY and LH screened and selected the studies for inclusion and performed the data extraction, synthesis and analysis. NN and LA retrieved the full-text studies and verified the extracted data. SY drafted the manuscript, which was reviewed by DM, LH, MEF and LA. All authors have approved the version of the manuscript submitted for publication. GAW is the guarantor.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.



Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs

Said Yousef http://orcid.org/0000-0002-4968-6918
Lamia Hayawi http://orcid.org/0000-0002-0153-5926
Alomgir Hossain http://orcid.org/0000-0002-7614-0072
Nazmun Nahar http://orcid.org/0009-0000-5685-3318
Doug Manuel http://orcid.org/0000-0003-0912-0845
lan Colman http://orcid.org/0000-0001-5924-0277
Emmanuel Papadimitropoulos http://orcid.org/0000-0002-3688-523X
MoezAllslam E Faris http://orcid.org/0000-0002-7970-2616
Leenah Abdelrazeq http://orcid.org/0009-0009-3005-306X
George A Wells http://orcid.org/0000-0002-2289-9139

REFERENCES

- 1 Yousef S, Colman I, Papadimitropoulos M, et al. Vitamin D and Chronic Diseases among First-Generation Immigrants: A Large-Scale Study Using Canadian Health Measures Survey (CHMS) Data. Nutrients 2022;14:1760.
- 2 Ankomah A, Byaruhanga J, Woolley E, et al. Double burden of malnutrition among migrants and refugees in developed countries: A mixed-methods systematic review. PLoS One 2022;17:e0273382.
- 3 Ichou M, Wallace M. The Healthy Immigrant Effect: The role of educational selectivity in the good health of migrants. *DemRes* 2019;40:61–94.
- 4 Chiu M, Austin PC, Manuel DG, et al. Cardiovascular risk factor profiles of recent immigrants vs long-term residents of Ontario: a multi-ethnic study. Can J Cardiol 2012;28:20–6.
- 5 De Maio FG, Kemp E. The deterioration of health status among immigrants to Canada. Glob Public Health 2010;5:462–78.
- 6 Newbold B. The short-term health of Canada's new immigrant arrivals: evidence from LSIC. Ethn Health 2009;14:315–36.
- 7 Sanou D, O'Reilly E, Ngnie-Teta I, et al. Acculturation and nutritional health of immigrants in Canada: a scoping review. J Immigr Minor Health 2014;16:24–34.
- 8 Vang Z, Sigouin J, Flenon A, et al. The Healthy Immigrant Effect in Canada: A Systematic Review. Population Change and Lifecourse Strategic Knowledge Cluster Discussion Paper Series/Un Réseau stratégique de connaissances Changements de population et parcours de vie Document de travail. 2015;3:4.
- 9 Canada Health. Canadian Research on Immigration and Health. Health Canada, Cat No H21- 149/1999E. 1999.
- 10 Kennedy S, McDonald JT, Biddle N. The Healthy Immigrant Effect and Immigrant Selection: Evidence from Four Countries. 2006.
- 11 Hansson E, Tuck A, Lurie S, et al. Improving mental health services for immigrant, refugee, ethno-cultural and racialized groups issues and options for service improvement for the task group of the services systems advisory committee, mental health commission of Canada. 2010.
- 12 Newbold B. Health status and health care of immigrants in Canada: a longitudinal analysis. *J Health Serv Res Policy* 2005;10:77–83A.

- 13 Pottie K, Greenaway C, Feightner J, et al. Evidence-based clinical guidelines for immigrants and refugees. CMAJ 2011;183:E824–925.
- 14 Beiser M. The International refugee crisis: British and Canadian responses - CLIO. After the door has been opened: the mental health of immigrants and refugees in Canada. 1993.
- Williams DR, Mohammed SA, Leavell J, et al. Race, socioeconomic status, and health: complexities, ongoing challenges, and research opportunities. Ann N Y Acad Sci 2010;1186:69–101.
- 16 Martin CA, Gowda U, Renzaho AMN. The prevalence of vitamin D deficiency among dark-skinned populations according to their stage of migration and region of birth: A meta-analysis. *Nutrition* 2016;32:21–32.
- 17 Spiro A, Buttriss JL. Vitamin D: An overview of vitamin D status and intake in Europe. *Nutr Bull* 2014;39:322–50.
- 18 Yousef S, Manuel D, Colman I, et al. Vitamin D Status among First-Generation Immigrants from Different Ethnic Groups and Origins: An Observational Study Using the Canadian Health Measures Survey. Nutrients 2021;13:2702.
- 19 Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in European and Middle East countries and strategies to prevent vitamin D deficiency: a position statement of the European Calcified Tissue Society. Eur J Endocrinol 2019;180:23–54.
- 20 Centers for Disease Control Prevention. Guidelines for evaluation of the nutritional status and growth in refugee children during the domestic medical screening examination, 2013. Available: https:// www.cdc.gov/immigrantrefugeehealth/pdf/Nutrition-and-Growth-Guidelines.pdf
- 21 Granlund L, Ramnemark A, Andersson C, et al. Prevalence of vitamin D deficiency and its association with nutrition, travelling and clothing habits in an immigrant population in Northern Sweden. Eur J Clin Nutr 2016;70:373–9.
- 22 Graham R, Mancher M, Wolman DM. Clinical practice guidelines we can trust. Washington, DC, 2011. Available: https://www.nap.edu/ catalog/13058
- 23 Kredo T, Bernhardsson S, Machingaidze S, et al. Guide to clinical practice guidelines: the current state of play. Int J Qual Health Care 2016;28:122–8.
- 24 Shiffman RN, Michel G, Essaihi A, et al. Bridging the guideline implementation gap: a systematic, document-centered approach to guideline implementation. J Am Med Inform Assoc 2004;11:418–26.
- 25 Rusińska A, Płudowski P, Walczak M, et al. Vitamin D Supplementation Guidelines for General Population and Groups at Risk of Vitamin D Deficiency in Poland-Recommendations of the Polish Society of Pediatric Endocrinology and Diabetes and the Expert Panel With Participation of National Specialist Consultants and Representatives of Scientific Societies-2018 Update. Front Endocrinol (Lausanne) 2018;9:246.
- 26 NICE. Vitamin D: supplement use in specific population groups. 2014;1–55.
- 27 Alberta Medical Association. Toward Optimized Practice (TOP) working group for vitamin D. Guideline for vitamin D testing and supplementation in adults. Edmonton, AB: Toward Optimized Practice, 2012.
- 28 Dai Z, Kroeger CM, McDonald S, et al. Methodological quality of public health guideline recommendations on vitamin D and calcium: a systematic review protocol. *BMJ Open* 2019:9:e031840.
- 29 Agbata EN, Padilla PF, Agbata IN, et al. Migrant Healthcare Guidelines: A Systematic Quality Assessment. J Immigr Minor Health 2019;21:401–13.
- 30 Swinkels H, Pottie K, Tugwell P, et al. Development of guidelines for recently arrived immigrants and refugees to Canada: Delphi consensus on selecting preventable and treatable conditions. CMAJ 2011;183:E928–32.
- 31 Ginde AA, Liu MC, Camargo CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009;169:626–32.
- 32 US Preventive Services Task Force. Calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: preventive medication. 2018.
- 33 British columbia guidelines. Vitamin d testing. In: Clinical practice guidelines and protocols in British Columbia. 2019.
- 34 Nutritional interventions update: vitamin D supplements during pregnancy. WHO Guidelines. 2020.
- 35 Pilz S, Zittermann A, Trummer C, et al. Vitamin D testing and treatment: a narrative review of current evidence. Endocr Connect 2019:8:R27–43
- 36 Hanley DA, Cranney A, Jones G, et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010;182:E610–8.



- 37 Brouwers MC, Kho ME, Browman GP, et al. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. *Can Med Assoc J* 2010;182:E472–8.
- 38 Brouwers MC, Hanna S, University M, et al. Appraisal of guidelines for research & evaluation II. 2017.
- 39 Hayawi LM, Graham ID, Tugwell P, et al. Screening for osteoporosis: A systematic assessment of the quality and content of clinical practice guidelines, using the AGREE II instrument and the IOM Standards for Trustworthy Guidelines. PLoS One 2018;13:e0208251.
- 40 Zhou X, Xu S, Ren Q, et al. Quality and Specific Concerns of Clinical Guidelines for Integrated Chinese and Western Medicine: A Critical Appraisal. Evid Based Complement Alternat Med 2020;2020.
- 41 Yousef S, Hayawi LM, Wells GA. n.d. A Systematic Assessment of the Quality and the Content of the Immigrant's Health and Vitamin D's Clinical Practice Guidelines (CPGs) using the AGREE II Instrument [PROSPERO #CRD420212405622021].
- 42 Yousef S, Hayawi L, Manuel D, et al. Assessment of the quality and content of clinical practice guidelines (CPGs) for vitamin D and for immigrants using the AGREE-II instrument: a protocol for systematic review. Syst Rev 2022;11:245.
- 43 Chandler J, Cumpston M, Li T, et al. Cochrane handbook for systematic reviews of interventions version 6.3. Cochrane, 2022. Available: www.training.cochrane.org/handbook
- 44 Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Int J Surg 2021;88:S1743-9191(21)00040-6.
- 45 De Boeck K, Castellani C, Elborn JS, et al. Medical consensus, guidelines, and position papers: a policy for the ECFS. *J Cyst Fibros* 2014:13:495–8.
- 46 Lunny C, Salzwedel DM, Liu T, et al. Validation of five search filters for retrieval of clinical practice guidelines produced low precision. J Clin Epidemiol 2020;117:109–16.
- 47 WHO. Report on the health of refugees and migrants in the WHO European region: no public health without refugee and migrant health. 2018.
- 48 WHO. World report on the health of refugees and migrants. 2022.
- 49 Brouwers Melissa C. Appraisal of guidelines for research & evaluation II -agree next steps consortium membership.2009. Available: www. agreetrust.org
- 50 Armstrong JJ, Rodrigues IB, Wasiuta T, et al. Quality assessment of osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal. Arch Osteoporos 2016;11:6.
- 51 Font-Gonzalez A, Mulder RL, Loeffen EAH, et al. Fertility preservation in children, adolescents, and young adults with cancer: Quality of clinical practice guidelines and variations in recommendations. Cancer 2016;122:2216–23.
- 52 Ou Y, Goldberg I, Migdal C, et al. A critical appraisal and comparison of the quality and recommendations of glaucoma clinical practice guidelines. *Ophthalmology* 2011;118:1017–23.
- 53 Hallgren KA. Computing Inter-Rater Reliability for Observational Data: An Overview and Tutorial. *Tutor Quant Methods Psychol* 2012;8:23:23–34.
- 54 Płudowski P, Kos-Kudła B, Walczak M, et al. Guidelines for Preventing and Treating Vitamin D Deficiency: A 2023 Update in Poland. Nutrients 2023;15:695.
- 55 World Health Organization. *Guideline: vitamin D supplementation in pregnant women.* Geneva, 2012.
- Marcinowska-Suchowierska E, Walicka M, Tałałaj M, et al. Vitamin D supplementation in adults - guidelines. *Endokrynol Pol* 2010;61:723–9.
- 57 Płudowski P, Karczmarewicz E, Bayer M, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol Pol 2013;64:319–27.
- 58 Moyer VA, Force USPST. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2013;158:691–6.

- 59 National Osteoporosis Society. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management [Guideline]. 2013;1–28. Available: https://strwebprdmedia.blob.core.windows.net/media/ef2ideu2/ros-vitamin-d-and-bone-health-in-adults-february-2020.pdf
- 60 Alberta Medical Association. Vitamin D Testing and Supplementation Alberta, Available: https://actt.albertadoctors.org/CPGs/Lists/CPGDocumentList/Vitamin%20D%20Testing%20and%20Supplementation.pdf
- 61 Maeda SS, Borba VZC, Camargo MBR, et al. Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. Arq Bras Endocrinol Metabol 2014;58:411–33.
- 62 SA Health Perinatal Practice Guideline. *Vitamin D status in pregnancy*. SA Health Perinatal Practice Guidelines, 2016.
- 63 Khadilkar A, Khadilkar V, Chinnappa J, et al. Prevention and treatment of vitamin D and calcium deficiency in children and adolescents: Indian Academy of Pediatrics (IAP) guidelines. Indian Pediatr 2017;54:567–73.
- 64 Royal Osteoporosis Society. Vitamin D and Bone Health: A Practical Clinical Guideline for Patient Management [Guideline]. 2018;1–25.
- 65 Haq A, Wimalawansa SJ, Pludowski P, et al. Clinical practice guidelines for vitamin D in the United Arab Emirates. J Steroid Biochem Mol Biol 2018;175:4–11.
- 66 Health Paediatric Clinical Practice Guideline. Vitamin D deficiency in children. SA Health Paediatric Clinical Practice Guidelines, 2018.
- 67 US Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Vitamin D Deficiency in Adults: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325:1436–42.
- 68 Casado E, Quesada J, Naves M, et al. SEIOMM recommendations on the prevention and treatment of vitamin D deficiency. Rev Osteoporos Metab Miner 2021;13:84–97.
- 69 Gupta P, Dabas A, Seth A, et al. Indian Academy of Pediatrics Revised (2021) Guidelines on Prevention and Treatment of Vitamin D Deficiency and Rickets. *Indian Pediatr* 2022;59:142–58.
- 70 Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011;96:1911–30.
- 71 Chaves NJ. Recommendations for comprehensive post-arrival health assessment for people from refugee-like backgrounds. *Aust Soc Infect Dis* 2016;1–189.
- 72 Tosti ME, Marceca M, Eugeni E, et al. Health assessment for migrants and asylum seekers upon arrival and while hosted in reception centres: Italian guidelines. Health Policy 2021;125:393–405.
- 73 Vignier N, Halley des Fontaines V, Billette de Villemeur A, et al. Public health issues and health rendezvous for migrants from conflict zones in Ukraine: A French practice guideline. *Infect Dis Now* 2022;52:193–201.
- 74 Mithal A, Wahl DA, Bonjour JP, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporosis International: Springer London, 2009:1807–20.
- 75 Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr 2016;103:1033–44.
- 76 Kung J, Miller RR, Mackowiak PA. Failure of clinical practice guidelines to meet institute of medicine standards: Two more decades of little, if any, progress. *Arch Intern Med* 2012;172:1628–33.
- 77 Vernooij RWM, Sanabria AJ, Solà I, et al. Guidance for updating clinical practice guidelines: a systematic review of methodological handbooks. *Impl Sci* 2014;9:3.
- 78 Yousef S, Papadimitropoulos M, Faris M, et al. Melanin levels in relation to vitamin D among first-generation immigrants from different ethnic groups and origins: A comparative national Canadian cross-sectional study. Front Med (Lausanne) 2022;9:992554.
- 79 Yousef S, Elliott J, Manuel D, et al. Study protocol: Worldwide comparison of vitamin D status of immigrants from different ethnic origins and native-born populations-a systematic review and metaanalysis. Syst Rev 2019;8:211.